Regeneron Pharmaceuticals, Inc. (REGN): Price and Financial Metrics

Regeneron Pharmaceuticals, Inc. (REGN)

Today's Latest Price: $609.17 USD

14.48 (-2.32%)

Updated Jul 1 4:00pm

Add REGN to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

REGN Stock Summary

  • Regeneron Pharmaceuticals Inc's market capitalization of $70,174,520,546 is ahead of 97.61% of US-listed equities.
  • REGN's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 2,143.41 -- higher than 98.05% of US-listed equities with positive expected earnings growth.
  • The price/operating cash flow metric for Regeneron Pharmaceuticals Inc is higher than 88.23% of stocks in our set with a positive cash flow.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Regeneron Pharmaceuticals Inc are AMD, VRTX, MU, AMAT, and NTES.
  • REGN's SEC filings can be seen here. And to visit Regeneron Pharmaceuticals Inc's official web site, go to
REGN Daily Price Range
REGN 52-Week Price Range

REGN Stock Price Chart Technical Analysis Charts

REGN Price/Volume Stats

Current price $609.17 52-week high $646.33
Prev. close $623.65 52-week low $271.37
Day low $601.02 Volume 984,748
Day high $625.00 Avg. volume 1,337,348
50-day MA $581.49 Dividend yield N/A
200-day MA $431.67 Market Cap 67.02B

Regeneron Pharmaceuticals, Inc. (REGN) Company Bio

Regeneron Pharmaceuticals is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for eye diseases, high LDL-cholesterol and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including oncology, rheumatoid arthritis, asthma, and atopic dermatitis. The company was founded in 1988 and is based in Tarrytown, New York.

REGN Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:

We started the process of determining a valid price forecast for Regeneron Pharmaceuticals Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Regeneron Pharmaceuticals Inc ranked in the 34th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 43.17%. The most interesting components of our discounted cash flow analysis for Regeneron Pharmaceuticals Inc ended up being:

  • Interest coverage, a measure of earnings relative to interest payments, is 90.22 -- which is good for besting 94.47% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
  • The business' balance sheet reveals debt to be 1% of the company's capital (with equity being the remaining amount). Approximately merely 5.2% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • REGN's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 55.41% of tickers in our DCF set.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as REGN, try JNJ, PDEX, PRAH, GSK, and XRAY.

REGN Latest News Stream

Event/TimeNews Detail
Loading, please wait...

REGN Latest Social Stream

Loading social stream, please wait...

View Full REGN Social Stream

Latest REGN News From Around the Web

Below are the latest news stories about Regeneron Pharmaceuticals Inc that investors may wish to consider to help them evaluate REGN as an investment opportunity.

REGN vs. TECH: Which Stock Is the Better Value Option?

REGN vs. TECH: Which Stock Is the Better Value Option?

Yahoo | July 1, 2020

Scott+Scott Attorneys at Law LLP Investigates Regeneron Pharmaceuticals, Inc.’s Directors and Officers for Breach of Fiduciary Duty – REGN

NEW YORK, July 01, 2020 -- Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a national securities and consumer rights litigation firm, is investigating whether certain.

Yahoo | July 1, 2020

Top Stocks for July 2020

The S&P 500 Index is a market-capitalization-weighted index of the 500 largest publicly traded companies in the U.S. It is widely regarded as the best gauge of large-cap U.S. equities. Some of the largest companies in the index include Microsoft Corp.

Yahoo | June 30, 2020

Regeneron Pharmaceuticals Has Made a Major Upside Breakout

Regeneron Pharmaceuticals recently made a significant upside breakout. Pretty amazing for a stock that has more than doubled in the past 12 months. Let's go over our charts and indicators so we can show you what we mean.

Yahoo | June 30, 2020

Investors shouldn't chase a potential COVID-19 vaccine winner: Analyst

ROBO Global Senior Research Analyst Nina Deka joins Yahoo Finance’s On The Move panel to address the dangers of chasing coronavirus vaccine stocks.

Yahoo | June 30, 2020

Read More 'REGN' Stories Here

REGN Price Returns

1-mo -1.37%
3-mo 23.48%
6-mo 65.02%
1-year 91.33%
3-year 24.90%
5-year 19.19%
YTD 62.24%
2019 0.53%
2018 -0.65%
2017 2.42%
2016 -32.38%
2015 32.33%

Continue Researching REGN

Want to see what other sources are saying about Regeneron Pharmaceuticals Inc's financials and stock price? Try the links below:

Regeneron Pharmaceuticals Inc (REGN) Stock Price | Nasdaq
Regeneron Pharmaceuticals Inc (REGN) Stock Quote, History and News - Yahoo Finance
Regeneron Pharmaceuticals Inc (REGN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9983 seconds.